4 m-opioid receptors (MORs) are necessary for the analgesic and addictive effects of opioids such as morphine, but the MORexpressing neuronal populations that mediate the distinct opiate effects remain elusive. Here we devised a new conditional bacterial artificial chromosome rescue strategy to show, in mice, that targeted MOR expression in a subpopulation of striatal direct-pathway neurons enriched in the striosome and nucleus accumbens, in an otherwise MOR-null background, restores opiate reward and opiate-induced striatal dopamine release and partially restores motivation to self administer an opiate. However, these mice lack opiate analgesia or withdrawal. We used Cre-mediated deletion of the rescued MOR transgene to establish that expression of the MOR transgene in the striatum, rather than in extrastriatal sites, is needed for the restoration of opiate reward. Our study demonstrates that a subpopulation of striatal direct-pathway neurons is sufficient to support opiate reward-driven behaviors and provides a new intersectional genetic approach to dissecting neurocircuit-specific gene function in vivo.
a r t I C l e S The endogenous opioid system in the brain is crucial for the processing of natural reward stimuli that drive behavioral reinforcement but has also been implicated in the abuse of addictive substances, including opiates, alcohol, nicotine and cannabinoids 1, 2 . After binding to endogenous opioid peptides (for example, enkephalin, β-endorphin or dynorphin) or exogenous opiate drugs (for example, morphine), the opioid receptors activate intracellular signaling through inhibitory G proteins, which typically leads to suppression of neuronal activity 2, 3 . The study of targeted gene-knockout mice has demonstrated that among the three major opioid receptors, MOR, δ and κ, only the MOR is essential for opiate reward, analgesia and dependence 4 . MORs are broadly expressed throughout the brain, and numerous pharmacological studies using local infusion of agonists or antagonists have provided important insights into the potential sites of MOR-mediated actions in the brain 1, 5 . However, the ability of such studies to draw firm conclusions as to which MOR-expressing neuronal populations mediate specific opiate effects are limited because of the mixtures of MOR-expressing neuronal populations in any given brain region and the fact that opioid receptors can be trafficked to distal axonal terminals to modulate presynaptic release 1, 5 .
The mammalian striatum, consisting of the dorsal striatum and nucleus accumbens (NAc), receives input from dopaminergic (DA) neurons in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) and is a key neuronal substrate for natural and drug rewards 1, 3 . Intriguingly, MOR expression in the striatum is enriched in clusters of medium spiny neurons (MSNs) that define the striosome (or patch) compartment, which is surrounded by the matrix compartment [5] [6] [7] . The striosome and matrix MSNs can be divided further into two subpopulations: those in the striatal direct pathway that send inhibitory projections to the substantia nigra (including both the substantia nigra pars reticulata and SNc) and those in the striatal indirect pathway that send inhibitory projections to the globus pallidus externa 6, 7 . Neuroanatomical tracing studies have suggested that striosome, rather than matrix, MSNs in the direct pathway preferentially form monosynaptic connections with DA neurons in the SNc and VTA 8, 9 . However, functional evidence for such inhibitory synaptic connections remains inconsistent 10 .
Previous evidence suggests that MORs are expressed in both directpathway and indirect-pathway MSNs in the striosome, but there appears to be an overabundance of direct-pathway MSNs in at least some striosomes 8, 9 . In this study, we devised a new conditional bacterial artificial chromosome (BAC) transgenic rescue strategy to assess directly the functional importance of MOR expression in striosomal and NAc directpathway MSNs in pathological opiate reward and reinforcement. a r t I C l e S
RESULTS

Re-expression of MOR in striatal direct-pathway neurons
The MOR-immunoreactive striosome compartment in the mouse is generally considered to contain both direct-pathway and indirectpathway MSNs 6, 7 . We confirmed this previous observation by double fluorescent localization of mouse MOR and GFP in the striata of GENSAT Drd1-GFP and Drd2-GFP BAC mice, which genetically label striatal direct-and indirect-pathway MSNs, respectively (Supplementary Fig. 1) 11 . We found both Drd1-GFP-and Drd2-GFP-labeled MSNs in the striosome (Supplementary Fig. 1a-f) . Moreover, using high-resolution confocal imaging, we found MOR expression in Drd1-GFP + direct-pathway MSNs ( Supplementary  Fig. 1g-i) , a result that is consistent with the interpretation that endogenous MOR is expressed in direct-pathway MSNs in the striosome. In this study, we sought to address whether MOR expression in the striatal neuronal subpopulation of the direct pathway modulates opiate-driven behavioral effects in vivo.
We used a new conditional BAC-mediated transgenic rescue strategy to re-express MOR in specific neuronal populations of MOR (also called Oprm1) knockout mice 4 . To target MOR expression to a pattern closely resembling that of endogenous MOR in direct-pathway MSNs, we used the GENSAT mouse Pdyn (encoding prodynorphin) BAC (RP23-358G23) 11 . This BAC drives GFP transgene expression in a relatively restricted pattern in the striatum, with the GFP-labeled striatal axonal projection pattern being consistent with the interpretation that the Pdyn BAC transgene drives GFP expression in direct-pathway MSNs 7,11 . By immunostaining for endogenous MOR in the striatum of Pdyn-GFP mice, we found that the GFP + neuronal patches in these mice were indeed colocalized with the MOR + striosome (Fig. 1a) . To further establish, at single-cell resolution, that the GFP + MSNs are indeed direct-pathway MSNs that also coexpress MOR, we performed fluorescence-activated cell sorting (FACS) of adult striatal neurons from either Pdyn-GFP or Drd2-GFP mice using our established protocol ( Supplementary Fig. 2) 12 , in which we selected single FACS-sorted GFP + neurons under the microscope and used them to prepare RNA for single-cell gene expression analyses 13 . All the single FACS-sorted neurons from both Pdyn-GFP and Drd2-GFP mice expressed Darpp-32 (also called Ppp1r1b) ( Fig. 1b) , which is an MSNspecific marker. Notably, RT-PCR analyses with two separate sets of MOR-specific primers showed that 32 out of 33 FACS-sorted single Pdyn-GFP + MSNs also expressed MOR. Moreover, these neurons also coexpressed two direct-pathway MSNs markers, Drd1 and Pdyn, but not a marker of indirect-pathway MSNs (Drd2). Conversely, single Drd2-GFP + neurons expressed Drd2 but not Drd1 or Pdyn and were also negative for MOR transcripts. These results support our conclusion that the Pdyn BAC selectively drives transgene expression in a subpopulation of direct-pathway MSNs that coexpress MOR in the striatum. Our result regarding MOR expression in the Drd2-GFP + neurons should be interpreted with caution for several reasons: we sampled only a relatively small number of such neurons, striosome MSNs comprise only about 20% of the total striatal MSNs, and there appears to be a higher abundance of direct-pathway MSNs within the striosome 6, 8 . Thus, we cannot exclude that a small subset of MOR + MSNs in the striosome are in the indirect pathway. In summary, our expression analyses support the use of the Pdyn BAC to drive the transgenic re-expression of MOR to interrogate the functional role of MOR specifically in this subpopulation of direct-pathway MSNs in opiate-driven behaviors in vivo.
To create Pdyn BAC transgenic mice re-expressing MOR, we reengineered the Pdyn BAC to first delete an extra gene on the BAC (Stk35; Fig. 1c ) and then inserted a mouse MOR cDNA followed by a poly(A) signal upstream of the Pdyn open reading frame to ensure that Pdyn itself is not overexpressed by the transgene. An innovative aspect of the BAC transgene design is the flanking of the MOR sequence with two loxP sites ( Fig. 1c ) so that the transgenic expression of MOR can be conditionally switched off in Cre-expressing cells. Pronuclear microinjection of this engineered BAC construct into inbred C57BL/6 embryos resulted in transgenic mice expressing MOR under the control of Pdyn genomic regulatory elements on the BAC (Pdyn-MOR mice). The Pdyn-MOR transgene was subsequently npg a r t I C l e S bred onto a MOR knockout background 4 to generate Pdyn-MOR/ MOR knockout (Rescue) mice. Using a highly selective MOR antibody 14 , we showed that MOR expression in the Rescue mouse brain was restricted largely to clusters of neurons in the striatum and NAc, with only a few extra-striatal regions, including layer I of the frontal cortex, hippocampus and parabrachial nucleus in the brain stem ( Fig. 1d-g and Supplementary Fig. 3 ). Because the Pdyn BAC drives transgene expression within the striatum and is highly selective for the subpopulation of direct-pathway MSNs in the striosome and NAc ( Fig. 1b and Supplementary Fig. 1 ) 6, 11 , we concluded that the Rescue mice confer re-expression of MOR in a subpopulation of directpathway MSNs that endogenously express MOR. We then used quantitative western blot analysis to determine the levels of MOR expression in the Rescue mice and found that these mice express MOR protein at about 2.76-fold the level of endogenous MOR in wild-type mice ( Supplementary Fig. 4 ). As previous viral-mediated targeted expression of other CNS genes has lead to conclusions regarding the crucial roles of re-expressed genes in specific brain regions in mediating various behavioral effects in vivo 15, 16 , we expect that the neuroanatomical and cellular specificity conferred by BAC-mediated re-expression of MOR in Rescue mice should also be informative regarding the role of direct-pathway MSN subpopulations in opiatedriven behaviors.
Morphine sensitization and place preference in Rescue mice
We next evaluated the phenotypic consequences of Pdyn BACdriven expression of MOR. We first showed that Pdyn-MOR and Rescue mice lacked general changes in development, locomotion or body weight despite modest levels of striatal MOR overexpression ( Supplementary Fig. 5 ). We next asked whether such targeted re-expression of MOR could restore any key opiate-driven behaviors that are absent in MOR knockout mice 4 . We first tested for the rewarding properties of morphine in the conditioned place preference (CPP) paradigm 4 . Using two independent cohorts of mice, we were able to reproducibly show lack of CPP in MOR knockout mice and restoration of CPP to wild-type control levels in Rescue mice ( Fig. 2a and Supplementary Fig. 6a ). Notably, transgenic overexpression of MOR in Pdyn-MOR mice did not elicit excessive levels of CPP compared to wild-type mice ( Fig. 2a ), suggesting a lack of gain-of-function effects on opiate reward by the transgene itself. These results demonstrate that targeted re-expression of MOR driven by the Pdyn promotor is sufficient to restore morphine-induced reward in vivo.
Morphine administration increases locomotor activity in mice, and repeated treatment progressively increases this locomotor response (sensitization), an effect that is absent in MOR knockout mice 4 . We next tested whether Rescue mice also express morphine-induced locomotion and sensitization. We found that morphine-induced locomotor stimulation and sensitization were absent in MOR knockout mice but were restored to wild-type levels in Rescue mice (Fig. 2b) . This result suggests that targeted MOR expression in striatal directpathway MSNs within the striosome and NAc is sufficient to not only mediate the locomotor stimulatory effects of morphine but also trigger a similar adaptive response to repeated morphine injections as that seen in wild-type mice.
Remifentanil self administration in Rescue mice
The CPP procedure tests the degree to which the rewarding effects of opioids, delivered noncontingently, can be conditioned to a context through repeated pairings. However, reward is only one dimension of the psychoactive properties of opiates that supports voluntary drug seeking and taking. The ability of a drug to act as a reinforcer of seeking and taking behavior is measured using self-administration procedures in which subjects engage in an action (for example, a lever press) to elicit the effects of the drug 17 . Such procedures provide a more direct and sensitive measure of the motivation to seek out the rewarding effects of the drug and arguably demonstrate closer construct and face validity as a model of human drug abuse behaviors 18 . Opioid receptors in a given neuronal population that are able to sustain opiate reward as measured by CPP may not necessarily sustain aspects of opioid reinforcement that are indexed by self administration 1 .
To address the role of MORs in striosomal and NAc direct-pathway MSNs in opiate-induced reinforcement, we trained rescue, MOR knockout and wild-type mice to self administer remifentanil, which is a potent short-acting synthetic opioid with a half-life of about 4 min (ref. 19) . In contrast to MOR knockout mice, which lacked any motivation to self administer remifentanil, both wild-type and Rescue mice obtained a stable level of remifentanil self administration across the last 3 d at the fixed-ratio 1 (FR1) reinforcement schedule (one lever press results in one infusion; Fig. 3a ). Further within-session analysis of the rate of infusions earned showed that both wild-type and Rescue mice obtained more infusions than MOR knockout mice during the 2-h session once stable self administration at FR1 had been obtained (Fig. 3b) . Moreover, there was no effect of genotype on inactive lever responding ( Fig. 3c) . This experiment demonstrates that Rescue mice, unlike MOR knockout mice, can acquire opioid self Figure 2 Restoration of the rewarding and locomotor effects of morphine by Pdyn BAC-driven expression of MOR in Rescue mice. (a) Morphineinduced CPP is absent in MOR knockout mice but is restored to wild-type levels in Rescue mice. Two-way analysis of variance (ANOVA) revealed a significant CPP deficit in MOR knockout mice (F (1, 26) = 61.14, P < 0.001, wild type compared to MOR knockout, two-way ANOVA; wild type, n = 7; MOR knockout, n = 8), which is restored in the Rescue mice (F (1, 26) = 3.619, P = 0.0683, wild type compared to Rescue, two-way ANOVA; wild type, n = 7; rescue, n = 8). Significant CPP was revealed by post hoc test in wild type (P < 0.001) and Rescue (P < 0.001) but not MOR knockout (P = 0.1642) mice. The morphine CPP in Pdyn-MOR transgenic mice is comparable to that in wild-type controls (F (1, 26) npg a r t I C l e S administration. However, further analyses revealed that the motivation to obtain remifentanil was only partially restored in these mice. First, Rescue mice earned infusions at a slower pace during FR1 testing ( Fig. 3a,b ) and gained fewer infusions overall during FR3 testing (three consecutive lever presses are required to trigger one infusion) ( Fig. 3d ) than wild-type mice. In addition, Rescue mice exhibited lower infusion 'break points' during a progressive ratio task, indicating that they were willing to exert less effort than wild-type mice to obtain the opiate drug ( Fig. 3e) . These results demonstrate that re-expression of MOR driven by the Pdyn promoter restores opioidseeking and opioid-taking behaviors that are lacking in the MOR knockout mice. Moreover, our results also suggest that full restoration of opiate reinforcement behavior may require MOR expression in other opiate-sensitive neuronal populations beyond the subpopulation of striatal direct-pathway MSNs.
Lack of opiate analgesia and withdrawal in Rescue mice
Chronic use of opiates leads to physical dependence that contributes to drug craving and relapse and is a major factor in the addiction cycle 20 . Physical withdrawal symptoms can be precipitated in wildtype but not MOR knockout mice by injecting the opiate antagonist naloxone in chronically morphine-treated animals 4 . Neither MOR knockout mice nor Rescue mice exhibited any of the classical signs of morphine withdrawal that were present in wild-type littermates after the chronic morphine regimen ( Fig. 4a and Supplementary Fig. 7) . This finding is consistent with the previous suggestion that MORs in other brain areas are the primary neuronal substrates for morphine physical withdrawal 21 .
A major clinical utility of opiates is analgesia, which is thought to be mediated by both spinal and supra-spinal activation of MOR 22 .
A role for the striatum in modulating opiate analgesia has been suggested 23 . To test whether MOR re-expression in the striatal directpathway MSN subpopulations can mediate opiate analgesia, we used two well-characterized tests. In both the hot-plate and tail-flick tests, morphine-induced analgesia was present in wild-type controls but was absent in both Rescue and MOR knockout mice (Fig. 4b,c) , suggesting that MOR expression outside the striosome and NAc directpathway MSNs is necessary for the analgesic effects of morphine in acute pain.
Opiate reward in Rescue mice requires striatal MOR To further strengthen the conclusion that the striatal directpathway MSN subpopulation is sufficient for opiate reward in Rescue mice, we performed an intersectional genetic approach, taking advantage of the conditional BAC transgene design (Fig. 1c) .
As the Pdyn-MOR transgene drives the re-expression of MOR in a few sites outside of the striatum, we crossed the Rgs9-cre transgene, which drives selective expression of Cre in all striatal MSNs (including both direct-pathway and indirect-pathway MSNs), onto the Rescue mouse background (Fig. 5a) 24 . The resulting Pdyn-MOR MOR knockout Rgs9-cre (Rescue-cre) mice had nearly complete elimination of MOR transgene expression in the striatal directpathway MSN subpopulation, which is the neuronal cell type that resides at the intersection between the Pdyn-MOR rescue transgene and the Rgs9-cre expression domains, leaving the expression of the MOR rescue transgene in the extrastriatal sites intact ( Fig. 5a and  Supplementary Fig. 8) . Notably, the Rescue-cre mice no longer exhibited morphine CPP under conditions in which their Rescue and wild-type littermates exhibited robust morphine CPP ( Fig. 5b and  Supplementary Fig. 6b) . Figure 3 Selective MOR expression in striosome and NAc direct-pathway MSNs partially rescues opiate self administration. (a) Wild-type and Rescue mice, but not MOR knockout mice, self administered remifentanil (0.10 mg per kg body weight intravenously) under the FR1 reinforcement schedule. Repeated-measures ANOVA analysis revealed a significant day × genotype interaction (F (18, 17) = 2.974, P = 0.015). Wild-type mice self administered more drug across days than MOR knockout mice (genotype × day: F (9,11) = 21.873, P < 0.001) and Rescue mice (F (9,13) = 3.485, P = 0.021), and Rescue mice self administered more drug than MOR knockout mice (F (9, 10 .072) = 4.920, P = 0.010). (b) The cumulative number of infusions earned during the 2-h session averaged over the last 3 d of FR1 showed that not only did wild-type and Rescue mice earn more infusions than MOR knockout mice, but wild-type mice also earned these infusions at earlier time points within the session than Rescue mice (wild type compared to MOR knockout, F (24,264) = 10.367, P < 0.001; Rescue compared to MOR knockout, F (24,240) = 2.506, P < 0.001; wild type compared to rescue, F (12, 156) npg a r t I C l e S Thus, our new BAC-mediated intersection genetic approach provides conclusive evidence that MOR expression in the direct-pathway MSNs, but not in extrastriatal sites, is responsible for restoring opiate reward in Rescue mice.
Morphine-induced striatal dopamine release in Rescue mice
Similarly to other drugs of abuse, morphine administration elicits dopamine release from the terminals of VTA and SNc neurons in the NAc and dorsal striatum, which is thought to contribute to the reinforcing and locomotor-activating effects 3, 25 . As VTA and SNc GABAergic interneurons express MORs 5,25 and tonically inhibit DA neurons 26 , the inhibitory action of morphine on these neurons has been postulated to mediate disinhibition of DA neurons 26 . Additionally, MOR agonists are also known to elicit somatodendritic release of dopamine from DA neurons in VTA 27 , which may contribute to the reinforcing effects of these drugs. The precise cellular mechanisms and roles of opioid-induced dopamine release in reward processing remain to be clarified 1, 28 .
To further probe the basal ganglia neurocircuitry mechanisms that are correlated with the rescue of opiate reward and reinforcement in our new model, we examined MOR expression in the VTA and SNc of wild-type, MOR knockout and Rescue mice. Unlike wild-type mice, our Rescue mice did not exhibit MOR staining of neuronal soma in VTA and SNc ( Fig. 6a-d) , which is consistent with the lack of GFP staining in VTA and SNc interneurons of Pdyn-GFP mice 11 . Moreover, Rescue mice showed neuropil MOR staining in the VTA and SNc that was abolished in Rescue-cre mice (Supplementary Fig. 8f,g) , suggesting that this reflects axonal terminal staining of MOR expressed in the striatal direct-pathway MSNs. Furthermore, double immunofluorescent staining showed that Rescue mice exhibited MOR terminal Figure 4 Pdyn BAC-driven expression of MOR in an otherwise MOR knockout background did not restore morphine analgesia or naloxoneprecipitated withdrawal. (a) Naloxone withdrawal, as quantified by the total withdrawal score, is not manifested in the Rescue mice. Naloxone precipitated significant withdrawal symptoms in morphine-treated wild-type mice but not Rescue mice or MOR knockout mice (t (14) = 10.07, P < 0.001, n = 8, wild type; t (12) = 0.2598, P = 0.7714, n = 7, MOR knockout; t (12) = 0.6430, P = 0.5811, n = 7, rescue; Student's t test, two tailed). Naloxone-precipitated withdrawal symptoms are not rescued in Rescue mice (F (1, 24) = 0.5187, P = 0.4783, MOR knockout compared to rescue, two-way ANOVA). (b) Morphine analgesia as measured by tail withdrawal is absent in Rescue mice compared to wild-type controls (Q (1) = 11.127, P = 0.003 for the genotype × treatment interaction, nonparametric two-way ANOVA for ranking; wild type, n = 8 per group; rescue, n = 7 per group). The deficits of the analgesia effect of morphine in MOR knockout mice measured by tail withdraw were not restored in Rescue mice (Q (1) = 0.191, P = 0.666 for the genotype × treatment interaction, nonparametric two-way ANOVA for ranking; n = 7 for all groups). (c) Morphine analgesia as measured by hot plate is absent in Rescue mice compared to wild-type controls (Q (1) = 8.808, P = 0.006 for the genotype × treatment interaction, nonparametric two-way ANOVA for ranking; wild type, n = 8 per group; rescue, n = 8 per group). The deficits of the analgesia effect of morphine in MOR knockout mice measured by tail withdraw were not restored in Rescue mice (Q (1) = 0.261, P = 0.613 for the genotype × treatment interaction, nonparametric two-way ANOVA for ranking; n = 8 for all groups). All values are shown as the mean ± s.e.m. ***P < 0.01. (Fig. 6e-g) . This result is consistent with studies demonstrating that striosomal direct-pathway MSNs may form monosynaptic contacts with DA neurons in the SNc and VTA 9 . To test whether MOR expression in striatal direct-pathway MSNs, but not midbrain interneurons, could restore in vivo morphine-induced dopamine efflux in the striatum, we performed dopamine microdialysis. Although the MOR knockout mice lacked any morphine-induced elevation in extracellular dopamine in the striatum, the Rescue mice exhibited full restoration of this effect to a level comparable with wild-type mice (Fig. 6h) . Saline injections had negligible effects (data not shown), and blockade of dopamine reuptake with cocaine elevated extracellular dopamine levels to similar extents across wild-type, MOR knockout and Rescue mice (Fig. 6i) . Together, these results suggest that restoration of MOR expression in the direct-pathway MSNs in the striosome and NAc is sufficient to rescue morphine-induced elevation of extracellular dopamine in the striatum (Supplementary Fig. 9) , an in vivo neurochemical correlate that is elicited by a variety of natural and drug rewards 29 .
DISCUSSION
In this study, we used a new conditional BAC rescue strategy in mice to demonstrate that targeted MOR expression in a subpopulation of striatal direct-pathway MSNs in the striosome and NAc restores opiate-induced CPP and sensitization and partially restores opiate reinforcement but does not rescue opiate analgesia and withdrawal. Because the MOR transgene is expressed in a few extrastriatal sites, we used Cre-mediated striatal-specific deletion of the rescue transgene to establish that MORs in the striatal direct-pathway MSNs are necessary for opiate reward in Rescue mice. Moreover, we also showed that Rescue mice exhibit morphine-induced elevation of extracellular dopamine levels in the striatum, providing evidence that MOR-expressing striatal direct-pathway MSNs can functionally regulate nigrostriatal dopamine release. Thus, our study provides in vivo evidence that MORs in striosomal and NAc direct-pathway neurons are sufficient to mediate opiate reward and reinforcement.
The anatomical basis of opiate reward processing is a neurobiologically and clinically important issue 1 . Previous knowledge of the neuronal substrate for opiate drug reward has been based largely on the influence of opioid receptor agonist or antagonist infusion into local brain regions on opiate reinforcement or place conditioning 1 . These studies provide strong evidence for VTA and NAc as key brain regions in the rewarding and reinforcing properties of opiates 1 . However, the mixture of multiple cell types expressing MORs in these brain regions precluded the identification of cell types that mediate the effects of the infused drugs. As previous genetic studies have demonstrated that the MOR is the only opioid receptor that is necessary for opiate reward, analgesia and dependence 4 , we reasoned that distinct MOR-expressing neuronal populations can be interrogated genetically for their roles in mediating opiate-induced behavioral effects in vivo. Our BAC-mediated targeted re-expression of MOR permitted us to address whether expression of MORs in a specific neuronal population is sufficient for opiate reward-related behaviors. The anatomical and cellular specificity of transgene expression driven by the Pdyn BAC was confirmed by our expression analyses of FACS-sorted single MSNs from Pdyn-GFP mice (Fig. 1b) .
Our study provides insights on a subpopulation of MOR-expressing direct-pathway MSNs, which normally reside in the striosome and NAc, in reward and reinforced behaviors. In demonstrating that Rescue mice can restore opiate-induced dopamine release in the striatum, as well as that such enhancement of striatal and NAc dopamine transmission is associated with opiate reinforcement, it is tempting to speculate that MOR function in this subset of direct-pathway MSNs can influence reinforced behaviors by regulating the activity of midbrain DA neurons. This hypothesis is based on the rationale that striosome direct-pathway MSNs are known to form monosynaptic GABAergic inputs onto the DA neurons in VTA and SNc 9 and that our Rescue mice had restored MOR expression in the striatonigral npg a r t I C l e S axonal terminals in VTA and SNc (Supplementary Fig. 8 ) and opiate-induced striatal dopamine release. Future in vitro and in vivo electrophysiological studies will be needed to address how MORs in the direct-pathway MSN neuronal subpopulations may regulate DA neuron activities in both Rescue and wild-type mice. Our findings are also consistent with the notion that MORs in multiple neuronal populations inside and outside the striatum could have a role in opiate reward-related behaviors. Although morphine CPP was restored in Rescue mice, remifentanil self administration in Rescue mice was only partially restored as compared to their wildtype littermates. This latter finding, in this arguably more sensitive assay of opioid drug reward, suggests the likely contribution of other MOR-expressing neuronal populations in regulating opiate reward and reinforcement. Indeed, MOR agonists have been shown to disinhibit DA neuron activity through suppression of presynaptic VTA interneurons 26 and GABAergic neurons in the rostromedial tegmental nucleus 29 . Moreover, other neuronal cell types such as the striatal cholinergic interneurons and neurons in the nucleus tractus solitarius have also been implicated in opiate reward 26, 30, 31 . Future MOR-based genetic studies should allow for the systematic interrogation of the roles of MOR in these opiate-sensitive neuronal cell populations in opiate reward and reinforcement.
Our study is an initial step in the dissection of the neuronal populations in which MOR synthesis may contribute to opiate reward. We are cognizant of several potential limitations of our approach based on the transgenic re-expression of MOR in MOR knockout mice. First, our genetic experiment was designed to address a sufficiency role of MOR in striatal direct-pathway neuronal subpopulations in opiate reward in vivo, and it does not address the related but independent question of whether MOR expression in the striatal direct-pathway MSNs is necessary for opiate reward and reinforcement. Complementary genetic studies with selective deletion of endogenous MOR in specific neuronal populations will be needed to address whether MOR expression in a given neuronal population is necessary for opiate-induced behaviors. Second, the transgenic re-expression of MOR based on the Pdyn BAC leads to MOR expression that is higher than the levels of endogenous MOR in the striatum, and the expression pattern of the MOR transgene may also have subtle differences (for example, at extrastriatal sites of expression) from endogenous MOR (Supplementary Fig. 3) . However, our results should still be interpretable, as we showed the colocalization of a Pdyn BAC-driven transgene with endogenous MOR in the striosomal direct-pathway MSNs at single-neuron resolution. Moreover, the Pdyn-MOR transgenic mice themselves did not appear to have overt basal or opiate-induced behavioral deficits, and the Rescue mice restored a subset of opiate-driven behaviors that are normally present in wild-type mice but are absent in MOR knockout mice. Hence, our results are consistent with the transgenic rescue of a loss-of-function mutant rather than new gain-of-function phenotypes elicited by the transgene. Such a classic transgenic rescue approach, with overexpression of the rescuing transgene by non-native promoters, has been used routinely in invertebrate genetic systems. Moreover, conceptually similar viral-mediated re-expression studies in mice have been highly informative on the circuit-specific roles of several CNS genes in behavioral control 15, 16 . To further strengthen the current observations, future genetic experiments should aim at conditional re-expression of MOR from the endogenous MOR genomic locus to assess whether the precise endogenous level of MOR in a given neuronal population can mediate certain opiate-driven behaviors. Our study also reveals a correlate, but not yet causal, role between restoration of opiate-induced striatal dopamine release and opiate reward in the Rescue mice. The precise mechanism through which the rescuing MOR transgene modulates DA neuron function remains to be defined. This is an important issue to resolve, as opiates are known to mediate reward through both dopamine-dependent and dopamine-independent mechanisms [32] [33] [34] , and striosomal directpathway MSNs also project to both the midbrain DA neurons and, to some extent, GABAergic neurons 8 , which may have distinct roles in opiate reward 33, 34 . Such limitations notwithstanding, our study is an important step forward toward a MOR-based genetic dissection of the roles of distinct neuronal populations in opiate-driven behaviors in vivo.
Our study provides some insight into the functional organization of striatal projection neuron circuitry and suggests a possible explanation for the restricted, striosome-specific pattern of MOR expression in the striatum. Striatal MSNs can be categorized on the basis of two distinct systems: the direct and indirect pathways, and the striosome and matrix compartments 6, 7 . These two-layered MSN categorization systems result in four distinct subtypes of MSNs based on their afferent and efferent connectivities and molecular marker expression 6, 7 . The availability of genetic access to the striatal direct-and indirectpathway MSNs, provided by GENSAT BAC transgenic mice 11 , enables rapid progress toward understanding the differential physiological functions of striatal direct-and indirect-pathway MSNs, including their roles in natural and drug rewards 35, 36 . However, these studies do not distinguish the direct-or indirect-pathway MSNs in striosome as compared to matrix compartments, even though such compartmentalization is thought to have an important role in basal ganglia function 37 . Our study shows that the Pdyn BAC confers some specificity to the striosomal direct-pathway MSNs, as expression analyses of FACS-purified single Pdyn-GFP neurons showed selective expression of direct-pathway markers (Drd1 and Pdyn) and a striosomal marker (MOR) but not the indirect-pathway marker (Drd2). The predominant, but not absolute, expression of MOR in the striosomal directpathway MSNs relative to the indirect-pathway MSNs has been noted previously in single-neuron tracing experiments 6, 8 . This observation is also consistent with the finding that genetic ablation of D1 MSNs (but preserving D2 MSNs) leads to the loss of the majority of MOR staining in the striatum 38 . Future studies will be needed to address the functional distinction of MOR expressed in the striatal directand indirect-pathway MSNs. Our study also offers some functional insight into the restricted, patchy pattern of MOR expression in the striatum 5, 6 and suggests that MORs in the striosomal direct-pathway MSNs may contribute to opiate reward. In addition, our in vivo striatal microdialysis experiment showed that MOR in the striosome and NAc direct-pathway MSNs can regulate striatal dopamine release. This finding is consistent with the interpretation that MOR + striatal direct-pathway MSNs are part of reciprocal neural circuits between the striatum and VTA and SNc DA neurons that are postulated to have important roles in reward and reinforcement behaviors 9, 37 .
Our study demonstrates a new intersectional genetic strategy to assess a single gene in a specific neuronal population for its physiological or pathological roles in a mammalian model. Previous mouse genetic tools, such as cre-and loxP-mediated conditional gene inactivation 39 , often cannot interrogate the role of a single neuronal population because the majority of available Cre mouse lines express the recombinase in multiple cell types in the brain. An intersectional genetic approach based on sequential use of Flp and Cre recombinases offers a solution for genetic access to a single cell type that is defined by the overlapping expression domains of the recombinases 40 . Our current study demonstrates an alternative strategy based on the conditional BAC rescue approach. We showed that the conditional BAC transgene design, with strategically placed loxP sites flanking npg a r t I C l e S MOR on the BAC, allows efficient and selective removal of the rescue MOR transgene only in a single neuronal cell type at the intersection of the BAC and Cre expression domains. Given the rich repertoire of publicly available knockout and Cre mouse lines, as well as wellcharacterized BAC transgenes 11 , we envision that the BAC-mediated intersectional genetic approach may help elucidate not only the cellular targets for opiate-induced effects, including reward, analgesia and dependence, but also the cell type-specific function of many other important genes in the mammalian brain.
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